The city of Naples, Florida, currently has 4 active clinical trials seeking participants for Ulcerative Colitis research studies.
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Gender:
All
Ages:
Between 16 years and 80 years
Trial Updated:
05/31/2024
Locations: Gastroenterology Group of Naples, Naples, Florida +3 locations
Conditions: Ulcerative Colitis
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2024
Locations: GI PROS Research, Naples, Florida
Conditions: Ulcerative Colitis
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study,... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2024
Locations: GI PROS, Inc., Naples, Florida
Conditions: Ulcerative Colitis
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
Recruiting
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/29/2024
Locations: GI Pros Research, Naples, Florida
Conditions: Ulcerative Colitis, Colitis, Ulcerative